{"id":"ritonavir-boosted-fosamprenavir","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Diarrhea"},{"rate":"10-20","effect":"Nausea"},{"rate":"5-15","effect":"Rash"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"10-20","effect":"Lipid abnormalities"}]},"_chembl":{"chemblId":"CHEMBL1664","moleculeType":"Small molecule","molecularWeight":"585.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fosamprenavir is a prodrug that is converted to amprenavir, which binds to and inhibits HIV protease, an enzyme essential for processing viral polyproteins and producing mature, infectious viral particles. Ritonavir acts as a pharmacokinetic booster by inhibiting cytochrome P450 3A4, dramatically increasing fosamprenavir plasma concentrations and allowing for lower, more convenient dosing while maintaining therapeutic efficacy.","oneSentence":"Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, and is boosted by ritonavir which inhibits its metabolism to increase drug levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:17.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection in treatment-naïve and treatment-experienced patients"}]},"trialDetails":[{"nctId":"NCT02302547","phase":"PHASE3","title":"Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2014-12","conditions":"HIV","enrollment":224},{"nctId":"NCT00817765","phase":"PHASE1","title":"Pharmacokinetic Study of Posaconazole Boosted Fosamprenavir","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2009-01","conditions":"HIV Infection, Fungal Infection","enrollment":24},{"nctId":"NCT01923311","phase":"PHASE2, PHASE3","title":"Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2013-08-26","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":31},{"nctId":"NCT02513147","phase":"PHASE4","title":"HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen","status":"COMPLETED","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2015-06","conditions":"HIV-1","enrollment":44},{"nctId":"NCT01348308","phase":"PHASE3","title":"Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2011-09","conditions":"HIV-1 Infection, AIDS","enrollment":407},{"nctId":"NCT01475838","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-11","conditions":"Acquired Immunodeficiency Syndrome, HIV Infections","enrollment":438},{"nctId":"NCT00708162","phase":"PHASE3","title":"Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2008-07","conditions":"HIV Infection","enrollment":724},{"nctId":"NCT01637233","phase":"","title":"MARCH Central Nervous System Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"HIV-1 Infection","enrollment":28},{"nctId":"NCT01637259","phase":"PHASE4","title":"MARCH Renal Substudy","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2012-06","conditions":"Proteinuria, HIV","enrollment":76},{"nctId":"NCT01252940","phase":"PHASE3","title":"Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-11","conditions":"HIV-1 Infection","enrollment":482},{"nctId":"NCT01222611","phase":"PHASE4","title":"HCV Evolution in HIV/HCV (Genotype 1) Coinfected Patients Treated With Fosamprenavir","status":"COMPLETED","sponsor":"Fundacion SEIMC-GESIDA","startDate":"2011-03","conditions":"Chronic HIV Infection, HCV Coinfection","enrollment":42},{"nctId":"NCT00242216","phase":"PHASE4","title":"\"The Once A Day Protease Inhibitor Regimens\"","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2004-05","conditions":"HIV Infections","enrollment":76},{"nctId":"NCT00727597","phase":"PHASE3","title":"A Study in Underrepresented Patient Population or Regimen Tolerability: SUPPoRT","status":"COMPLETED","sponsor":"Georgetown University","startDate":"2008-07","conditions":"Human Immunodeficiency Virus Infections","enrollment":101},{"nctId":"NCT01010399","phase":"PHASE4","title":"Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects","status":"COMPLETED","sponsor":"Felizarta, Franco, M.D.","startDate":"2009-09","conditions":"Hypertriglyceridemia, HIV Infection","enrollment":36},{"nctId":"NCT00122603","phase":"PHASE2","title":"Dual Boosted Protease Inhibitor Regimens Without Any Additional Antiretroviral Therapy in HIV-1 Infected Patients (ANRS127)","status":"COMPLETED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-12","conditions":"HIV Infections","enrollment":61},{"nctId":"NCT00363142","phase":"PHASE3","title":"A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05","conditions":"HIV Infection, Infection, Human Immunodeficiency Virus","enrollment":211},{"nctId":"NCT00144833","phase":"PHASE3","title":"Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2005-03","conditions":"HIV-1","enrollment":150}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"VIROLOGIC FAILURE"},{"count":1,"reaction":"CREATININE RENAL CLEARANCE DECREASED"},{"count":1,"reaction":"DIABETES INSIPIDUS"},{"count":1,"reaction":"FANCONI SYNDROME"},{"count":1,"reaction":"HEPATITIS ACUTE"},{"count":1,"reaction":"IRIDOCYCLITIS"},{"count":1,"reaction":"KAPOSI'S SARCOMA"},{"count":1,"reaction":"LARYNGEAL PAIN"},{"count":1,"reaction":"MYCOBACTERIUM AVIUM COMPLEX INFECTION"},{"count":1,"reaction":"PANCREATITIS ACUTE"}],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lexiva plus Norvir"],"phase":"marketed","status":"active","brandName":"ritonavir-boosted fosamprenavir","genericName":"ritonavir-boosted fosamprenavir","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fosamprenavir is a protease inhibitor that blocks HIV protease, preventing viral replication, and is boosted by ritonavir which inhibits its metabolism to increase drug levels. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}